

# Steven Joniau

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8710819/steven-joniau-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382  
papers

18,055  
citations

59  
h-index

128  
g-index

606  
ext. papers

21,775  
ext. citations

4.3  
avg, IF

6.36  
L-index

#	Paper	IF	Citations
382	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , <b>2017</b> , 71, 618-629	10.2	1939
381	EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. <i>European Urology</i> , <b>2014</b> , 65, 124-37	10.2	1360
380	EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. <i>European Urology</i> , <b>2011</b> , 59, 61-71	10.2	1112
379	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>European Urology</i> , <b>2014</b> , 65, 467-79	10.2	965
378	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 71, 630-642	10.2	924
377	EAU guidelines on prostate cancer. <i>European Urology</i> , <b>2008</b> , 53, 68-80	10.2	848
376	Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 446-453	2.2	578
375	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>European Urology</i> , <b>2011</b> , 59, 572-83	10.2	386
374	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , <b>2018</b> , 50, 928-936	36.3	340
373	Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. <i>International Journal of Cancer</i> , <b>2002</b> , 98, 19-22	7.5	283
372	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. <i>European Urology</i> , <b>2017</b> , 72, 250-266	10.2	218
371	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , <b>2017</b> , 72, 84-109	10.2	203
370	Selective activation of the fatty acid synthesis pathway in human prostate cancer. <i>International Journal of Cancer</i> , <b>2000</b> , 88, 176-9	7.5	188
369	Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. <i>European Urology</i> , <b>2010</b> , 57, 466-71	10.2	174
368	Radiotherapy for renal-cell carcinoma. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e170-7	21.7	169
367	Mapping of pelvic lymph node metastases in prostate cancer. <i>European Urology</i> , <b>2013</b> , 63, 450-8	10.2	163
366	New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. <i>European Urology</i> , <b>2016</b> , 70, 161-175	10.2	154

365	Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e404-14	21.7	152
364	Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. <i>European Urology</i> , <b>2015</b> , 67, 74-82	10.2	149
363	Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. <i>BJU International</i> , <b>2010</b> , 106, 462-9	5.6	145
362	Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. <i>European Urology</i> , <b>2011</b> , 60, 205-10	10.2	140
361	Contemporary management of small renal masses. <i>European Urology</i> , <b>2011</b> , 60, 501-15	10.2	137
360	Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. <i>Journal of Magnetic Resonance Imaging</i> , <b>2013</b> , 37, 1392-401	5.6	135
359	Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. <i>European Urology</i> , <b>2015</b> , 67, 157-164	10.2	133
358	Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. <i>European Urology</i> , <b>2014</b> , 65, 1078-83	10.2	132
357	Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. <i>European Urology</i> , <b>2012</b> , 62, 472-87	10.2	129
356	Early salvage radiotherapy following radical prostatectomy. <i>European Urology</i> , <b>2014</b> , 65, 1034-43	10.2	128
355	Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. <i>European Urology</i> , <b>2011</b> , 60, 125-30	10.2	128
354	Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. <i>European Urology</i> , <b>2007</b> , 51, 121-8; discussion 128-9	10.2	125
353	Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. <i>European Urology</i> , <b>2010</b> , 58, 1-7; discussion 10-1	10.2	123
352	Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. <i>European Urology</i> , <b>2010</b> , 58, 96-104	10.2	120
351	Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life. <i>European Urology</i> , <b>2007</b> , 51, 614-20	10.2	114
350	High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. <i>Journal of Pathology</i> , <b>2005</b> , 206, 214-9	9.4	108
349	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , <b>2017</b> , 72, 869-885	10.2	106
348	Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. <i>BJU International</i> , <b>2011</b> , 107, 765-770	5.6	99

347	Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. <i>European Urology</i> , <b>2014</b> , 66, 479-86	10.2	94
346	Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. <i>European Urology</i> , <b>2012</b> , 61, 584-92	10.2	94
345	Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. <i>Cancer Research</i> , <b>2014</b> , 74, 2591-603	10.1	94
344	Identification of telocytes in the upper lamina propria of the human urinary tract. <i>Journal of Cellular and Molecular Medicine</i> , <b>2012</b> , 16, 2085-93	5.6	90
343	Toxicities of targeted therapy and their management in kidney cancer. <i>European Urology</i> , <b>2011</b> , 59, 526-40.2	10.2	89
342	An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. <i>European Urology</i> , <b>2008</b> , 53, 253-9	10.2	88
341	Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. <i>BJU International</i> , <b>2008</b> , 101 Suppl 2, 5-10	5.6	87
340	Small renal mass biopsy--how, what and when: report from an international consensus panel. <i>BJU International</i> , <b>2014</b> , 113, 854-63	5.6	86
339	Emerging mechanisms of enzalutamide resistance in prostate cancer. <i>Nature Reviews Urology</i> , <b>2014</b> , 11, 712-6	5.5	85
338	Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. <i>Molecular Endocrinology</i> , <b>2013</b> , 27, 2028-40		85
337	Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , <b>2014</b> , 14, 671	4.8	81
336	Androgen receptor antagonists for prostate cancer therapy. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, T105-18.7	5.7	80
335	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , <b>2016</b> , 69, 728-733	10.2	78
334	Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. <i>European Urology</i> , <b>2013</b> , 63, 693-701	10.2	78
333	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. <i>Critical Reviews in Oncology/Hematology</i> , <b>2010</b> , 73, 68-91	7	78
332	Natural history of surgically treated high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 163.e7-13	2.8	77
331	The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. <i>European Urology</i> , <b>2014</b> , 66, 191-9	10.2	76
330	The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. <i>BJU International</i> , <b>2016</b> , 118, 44-52	5.6	72

329	Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. <i>European Urology</i> , <b>2013</b> , 63, 646-52	10.2	70
328	Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial. <i>European Urology</i> , <b>2013</b> , 64, 766-72	10.2	65
327	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , <b>2021</b> , 53, 65-75	36.3	62
326	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , <b>2017</b> , 71, 886-893	10.2	61
325	Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1185-96	10.3	60
324	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. <i>European Urology</i> , <b>2019</b> , 75, 176-183	10.2	60
323	Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. <i>BJU International</i> , <b>2014</b> , 114, 81-9	5.6	58
322	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , <b>2018</b> , 9, 2256	17.4	57
321	Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e65064	3.7	55
320	Vaccine therapy in patients with renal cell carcinoma. <i>European Urology</i> , <b>2009</b> , 55, 1333-42	10.2	55
319	Current status of minimally invasive ablative techniques in the treatment of small renal tumours. <i>European Urology</i> , <b>2007</b> , 51, 328-36	10.2	55
318	Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 109.e23-31	2.8	53
317	Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. <i>European Urology</i> , <b>2016</b> , 69, 802-20	10.2	52
316	A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. <i>Journal of Urology</i> , <b>2013</b> , 189, 1930-8	2.5	52
315	Is surveillance an option for the treatment of small renal masses?. <i>European Urology</i> , <b>2007</b> , 52, 1323-30	10.2	49
314	The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1702-12	6.1	48
313	Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology. <i>European Journal of Radiology</i> , <b>2012</b> , 81, e217-22	4.7	48
312	Phase 2 Study of Tc-Trofolostat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1408-1413	8.9	46

311	Prospective evaluation of urinary incontinence, voiding symptoms and quality of life after open and robot-assisted radical prostatectomy. <i>BJU International</i> , <b>2013</b> , 112, 936-43	5.6	46
310	Outcome of nephron-sparing surgery for T1b renal cell carcinoma. <i>BJU International</i> , <b>2009</b> , 103, 1344-8	5.6	46
309	A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. <i>European Urology</i> , <b>2007</b> , 51, 388-94; discussion 395-6	10.2	45
308	Is there an additional value of $^{18}\text{F}$ -choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 1486-92	4.92	41
307	Metabolic changes after urinary diversion. <i>Advances in Urology</i> , <b>2011</b> , 2011, 764325	1.6	41
306	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , <b>2018</b> , 73, 436-444	10.2	41
305	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 484.e19-484.e25	2.8	39
304	Comparing the rules of engagement of androgen and glucocorticoid receptors. <i>Cellular and Molecular Life Sciences</i> , <b>2017</b> , 74, 2217-2228	10.3	37
303	MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 21414-34	6.3	37
302	Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. <i>BJU International</i> , <b>2017</b> , 120, 815-821	5.6	36
301	Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2003</b> , 6, 305-10	6.2	35
300	Clinical experience with the N-shaped ileal neobladder: assessment of complications, voiding patterns, and quality of life in our series of 58 patients. <i>European Urology</i> , <b>2005</b> , 47, 666-72; discussion 672-3	10.2	35
299	Segmental testicular infarction: conservative management is feasible and safe. <i>European Urology</i> , <b>2008</b> , 53, 441-5	10.2	34
298	Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. <i>Journal of Urology</i> , <b>2019</b> , 202, 725-731	7.51	34
297	Adipose-derived Stem Cells Counteract Urethral Stricture Formation in Rats. <i>European Urology</i> , <b>2016</b> , 70, 1032-1041	10.2	34
296	A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 474-9	5.3	33
295	Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. <i>Radiation Oncology</i> , <b>2007</b> , 2, 29	4.2	33
294	Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10-10	2.2	33

293	Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2012</b> , 46, 164-71		32
292	Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. <i>European Urology Oncology</i> , <b>2019</b> , 2, 174-188	6.7	32
291	The indications for partial nephrectomy in the treatment of renal cell carcinoma. <i>Nature Reviews Urology</i> , <b>2006</b> , 3, 198-205		31
290	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , <b>2020</b> , 78, 661-669	10.2	30
289	Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e205-14	3.3	30
288	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. <i>European Urology</i> , <b>2018</b> , 74, 474-480	10.2	29
287	Predictive factors for local recurrence after glansectomy and neoglans reconstruction for penile squamous cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 141-146	2.8	29
286	Pelvic exenterations for gynecological malignancies: a study of 36 cases. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 889-96	3.5	29
285	Urea-splitting urinary tract infection contributing to hyperammonemic encephalopathy. <i>Nature Reviews Urology</i> , <b>2007</b> , 4, 455-8		29
284	Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. <i>World Journal of Urology</i> , <b>2013</b> , 31, 1073-80	4	28
283	Percutaneous ultrasound-guided radiofrequency ablation of recurrent renal cell carcinoma in renal allograft after partial nephrectomy. <i>Urology</i> , <b>2006</b> , 67, 199	1.6	28
282	The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making. <i>BioMed Research International</i> , <b>2014</b> , 2014, 627510	3	27
281	Continent catheterizable vesicostomy in an adult population: success at high costs. <i>Neurourology and Urodynamics</i> , <b>2009</b> , 28, 487-91	2.3	27
280	Occurrence of both bladder and prostate cancer in five cancer registries in Belgium, The Netherlands and the United Kingdom. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 1694-700	7.5	27
279	Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical Aspects of Radical Prostatectomy. <i>EAU Update Series</i> , <b>2005</b> , 3, 90-97		27
278	Idiopathic partial thrombosis of the corpus cavernosum: conservative management is effective and possible. <i>European Urology</i> , <b>2003</b> , 44, 119-23	10.2	27
277	Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines. <i>PLoS ONE</i> , <b>2014</b> , 9, e90002	3.7	27
276	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , <b>2018</b> , 73, 512-518	10.2	27

275	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e605-e612	3.3	27
274	Current vaccination strategies for prostate cancer. <i>European Urology</i> , <b>2012</b> , 61, 290-306	10.2	26
273	Debulking surgery in the setting of very high-risk prostate cancer scenarios. <i>BJU International</i> , <b>2012</b> , 110, E192-8	5.6	26
272	Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 1849-61	4.9	25
271	DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0130651	3.7	25
270	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4064-4075	2.2	25
269	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. <i>Scientific Reports</i> , <b>2019</b> , 9, 13786	4.9	24
268	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Acta Oncologica</i> , <b>2014</b> , 53, 1413-22	3.2	24
267	Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia. <i>Urology</i> , <b>2007</b> , 69, 1102-6	1.6	24
266	Metanephric adenoma during pregnancy: clinical presentation, histology, and cytogenetics. <i>Human Pathology</i> , <b>2006</b> , 37, 1227-32	3.7	24
265	Prostatic intraepithelial neoplasia (PIN): importance and clinical management. <i>European Urology</i> , <b>2005</b> , 48, 379-85	10.2	24
264	Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "EUROBLIS". <i>European Urology</i> , <b>2020</b> , 78, 699-709	10.2	23
263	Evaluating a decision aid for patients with localized prostate cancer in clinical practice. <i>Urologia Internationalis</i> , <b>2008</b> , 81, 383-8	1.9	23
262	Detection of clinical unilateral T3a prostate cancer - by digital rectal examination or transrectal ultrasonography?. <i>BJU International</i> , <b>2006</b> , 98, 982-5	5.6	23
261	Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. <i>Oncotarget</i> , <b>2016</b> , 7, 24326-38	3.3	23
260	Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. <i>European Urology Oncology</i> , <b>2021</b> , 4, 305-309	6.7	23
259	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2392-8	10.3	22
258	The genomic landscape of prostate cancer. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 10822-51.3		21

257	Indications, techniques and outcomes for pelvic exenteration in gynecological malignancy. <i>Current Opinion in Oncology</i> , <b>2014</b> , 26, 514-20	4.2	20
256	International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. <i>European Urology</i> , <b>2011</b> , 60, 673-83	10.2	20
255	How Important Are Surgical Margins in Nephron-Sparing Surgery?. <i>European Urology Supplements</i> , <b>2007</b> , 6, 533-539	0.9	20
254	Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2003</b> , 6, 61-5	6.2	20
253	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1159-1167	13.4	19
252	Reliability of sentinel node procedure for lymph node staging in prostate cancer patients at high risk for lymph node involvement. <i>Acta Oncologica</i> , <b>2015</b> , 54, 896-902	3.2	19
251	Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2015</b> , 18, 31-7	6.2	19
250	Complications and functional results of surgery for locally advanced prostate cancer. <i>Advances in Urology</i> , <b>2012</b> , 2012, 706309	1.6	19
249	Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. <i>Advances in Urology</i> , <b>2008</b> , 594868	1.6	19
248	Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy. <i>BJU International</i> , <b>2007</b> , 99, 311-4	5.6	19
247	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1621-1627	4	18
246	Hypofractionated palliative radiotherapy for bladder cancer. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 181-186	9	18
245	Molecular underpinnings of enzalutamide resistance. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, R545-R557	5.7	18
244	RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1313-22	8.7	18
243	Idiopathic partial thrombosis of the corpus cavernosum: aetiology, diagnosis and treatment. <i>Scandinavian Journal of Urology</i> , <b>2013</b> , 47, 163-8	1.6	18
242	Results of surgery for high-risk prostate cancer. <i>Current Opinion in Urology</i> , <b>2013</b> , 23, 342-8	2.8	18
241	Is there a prostate-specific antigen upper limit for radical prostatectomy?. <i>BJU International</i> , <b>2011</b> , 108, 1093-100	5.6	18
240	Polypoid endometriosis of the bladder during pregnancy mimicking urachal carcinoma. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2011</b> , 38, 475-8	5.8	18

239	Renal cell carcinoma with synchronous metastasis to the calcaneus and metachronous metastases to the ovary and gallbladder. <i>Case Reports in Medicine</i> , <b>2011</b> , 2011, 671645	0.7	18
238	Effects of sex hormone-binding globulin (SHBG) on androgen bioactivity in vitro. <i>Molecular and Cellular Endocrinology</i> , <b>2016</b> , 437, 280-291	4.4	17
237	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of Ga-PSMA and C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , <b>2020</b> , 204, 296-302	2.5	17
236	Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. <i>BJU International</i> , <b>2016</b> , 118, 890-901	5.6	16
235	The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: a systematic review. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 110, 45-54	5.3	16
234	Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease. <i>Journal of Urology</i> , <b>2012</b> , 188, 84-90	2.5	16
233	Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. <i>BMC Urology</i> , <b>2012</b> , 12, 8	2.2	16
232	Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (T3b). <i>BJU International</i> , <b>2008</b> , 101, 444-9	5.6	16
231	Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e784-e792	3.3	15
230	Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1857-1866	4	15
229	The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2017</b> , 20, 407-412	6.2	14
228	Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLADder cancer Trial. <i>European Journal of Cancer</i> , <b>2016</b> , 69, 9-18	7.5	14
227	Kidney radiofrequency ablation for small renal tumors: oncologic efficacy. <i>Journal of Endourology</i> , <b>2010</b> , 24, 721-8	2.7	14
226	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 234.e13-9	2.8	13
225	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>Frontiers in Surgery</i> , <b>2016</b> , 3, 65	2.3	13
224	Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1507-1515	4	12
223	PCA: prostate cancer, patient-centred approach or both?. <i>BJU International</i> , <b>2012</b> , 110, 16-22	5.6	12
222	Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation?. <i>Strahlentherapie Und Onkologie</i> , <b>2013</b> , 189, 789-95	4.3	12

221	Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 960-7	4	12
220	Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?. <i>BJU International</i> , <b>2013</b> , 111, 1021-30	5.6	12
219	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , <b>2020</b> , 38, 1959-1968	4	12
218	Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , <b>2020</b> , 37, 512-526	4.1	12
217	Intratunical Injection of Human Adipose Tissue-Derived Stem Cells Restores Collagen III/I Ratio in a Rat Model of Chronic Peyronie's Disease. <i>Sexual Medicine</i> , <b>2019</b> , 7, 94-103	2.7	12
216	Diagnostic Value of F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , <b>2020</b> , 3, 73-79	6.7	12
215	Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. <i>European Urology</i> , <b>2015</b> , 67, 319-25	10.2	11
214	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , <b>2018</b> , 52, 216-227	12.7	11
213	The role of TET-mediated DNA hydroxymethylation in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2018</b> , 462, 41-55	4.4	11
212	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2018</b> , 462, 56-63	4.4	11
211	Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. <i>World Journal of Urology</i> , <b>2016</b> , 34, 1367-72	4	11
210	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , <b>2011</b> , 35, 565-579	0.1	11
209	Ablative therapies in the treatment of small renal tumors: how far from standard of care?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2010</b> , 28, 251-9	2.8	11
208	Open surgery for localized RCC. <i>Scientific World Journal, The</i> , <b>2007</b> , 7, 742-52	2.2	11
207	Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , <b>2020</b> , 37, 501-511	4.1	11
206	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in BT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 96, 333-340	4	11
205	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. <i>European Urology</i> , <b>2019</b> , 75, 817-825	10.2	11
204	Optimal Ga-PSMA and F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 1211-1218	8.8	11

203	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. <i>BMC Cancer</i> , <b>2018</b> , 18, 354	4.8	10
202	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. <i>European Urology Oncology</i> , <b>2019</b> , 2, 589-596	6.7	10
201	Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement. <i>Acta Oncologica</i> , <b>2013</b> , 52, 1336-44	3.2	10
200	Tumour-related imaging parameters predicting the percentage of preserved normal renal parenchyma following nephron sparing surgery: a retrospective study. <i>European Radiology</i> , <b>2013</b> , 23, 280-6	8	10
199	Results of buccal mucosa grafts for repairing long bulbar urethral strictures. <i>BJU International</i> , <b>2010</b> , 105, 1170-2	5.6	10
198	Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. <i>Advances in Urology</i> , <b>2012</b> , 2012, 983058	1.6	10
197	Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results. <i>Journal of Urology</i> , <b>2019</b> , 201, 315-321	2.5	10
196	What is the Need for Prostatic Biomarkers in Prostate Cancer Management?. <i>Current Urology Reports</i> , <b>2015</b> , 16, 70	2.9	9
195	Bilateral renal cell carcinoma development in long-term Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , <b>2007</b> , 30, 830-1	5.4	9
194	Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2015</b> , 8, 9522-32	1.4	9
193	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , <b>2021</b> , 4, 150-169	6.7	9
192	Intratunical injection of stromal vascular fraction prevents fibrosis in a rat model of Peyronie's disease. <i>BJU International</i> , <b>2019</b> , 124, 342-348	5.6	9
191	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , <b>2019</b> , 76, 443-449	10.2	8
190	Salvage Radiotherapy for Prostate Cancer. <i>Clinical Oncology</i> , <b>2020</b> , 32, 156-162	2.8	8
189	Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients. <i>American Journal of Pathology</i> , <b>2018</b> , 188, 795-804	5.8	8
188	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , <b>2018</b> , 74, 134-137	10.2	8
187	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. <i>European Urology Focus</i> , <b>2018</b> , 4, 369-375	5.1	8
186	Oligometastatic prostate cancer: Metastases-directed therapy?. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2016</b> , 14, 179-82	1.7	8

185	Characterization of subepithelial interstitial cells in normal and pathological human prostate. <i>Histopathology</i> , <b>2014</b> , 65, 418-28	7.3	8
184	Active surveillance for small renal tumors: have clinical concerns been addressed so far?. <i>International Journal of Urology</i> , <b>2013</b> , 20, 356-61	2.3	8
183	Open to debate. The motion: Nomograms should become a routine tool in determining prostate cancer prognosis. <i>European Urology</i> , <b>2009</b> , 55, 743-7	10.2	8
182	The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. <i>Advances in Urology</i> , <b>2012</b> , 2012, 612707	1.6	8
181	The Use of IIEF-5 for Reporting Erectile Dysfunction Following Nerve-Sparing Radical Retropubic Prostatectomy. <i>The Open Prostate Cancer Journal</i> , <b>2009</b> , 2, 1-9		8
180	Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1775-1781	4	8
179	Endovascular Management of Severe Arterial Haemorrhage After Radical Prostatectomy: A Case Series. <i>CardioVascular and Interventional Radiology</i> , <b>2017</b> , 40, 1698-1705	2.7	7
178	Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification. <i>Urology</i> , <b>2019</b> , 130, 113-119	1.6	7
177	Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. <i>Acta Oncologica</i> , <b>2016</b> , 55, 329-40	3.2	7
176	Current Management of pT3b Prostate Cancer After Robot-assisted Laparoscopic Prostatectomy. <i>European Urology Oncology</i> , <b>2019</b> , 2, 110-117	6.7	7
175	Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium. <i>Cancer</i> , <b>2017</b> , 123, 4139-4146	6.4	7
174	Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Prostate</i> , <b>2017</b> , 77, 3-9	4.2	7
173	Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?. <i>BJU International</i> , <b>2015</b> , 115, 364-72	5.6	7
172	Salvage radical prostatectomy in nonmetastatic castration-resistant prostate cancer patients who received previous radiotherapy: a feasibility study. <i>European Urology</i> , <b>2014</b> , 65, 254-5	10.2	7
171	Segmental testicular infarction. Conservative management is feasible and safe: part 2. <i>European Urology</i> , <b>2008</b> , 53, 656-8	10.2	7
170	Prepubic urethrectomy during radical cystoprostatectomy. <i>European Urology</i> , <b>2007</b> , 51, 915-21	10.2	7
169	Open Surgical Treatment of Localised Renal Cell Cancer. <i>EAU Update Series</i> , <b>2003</b> , 1, 220-225		7
168	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. <i>JMIR Research Protocols</i> , <b>2018</b> , 7, e11256	2	7

167	Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL. <i>Annals of Oncology</i> , <b>2019</b> , 30, v891-v892	10.3	7
166	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1543-1549	4	6
165	Patient-reported outcomes after buccal mucosal graft urethroplasty for bulbar urethral strictures: results of a prospective single-centre cohort study. <i>BJU International</i> , <b>2020</b> , 126, 684-693	5.6	6
164	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , <b>2020</b> , 78, 779-782	10.2	6
163	Incidental Detection of Occult Thyroid Carcinoma with C-Choline PET/CT for High Risk Prostate Cancer. <i>Current Urology</i> , <b>2017</b> , 10, 217-220	1.7	6
162	Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy. <i>European Urology Focus</i> , <b>2018</b> , 4, 288-293	5.1	6
161	Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 280	5.3	6
160	Idiopathic Partial Thrombosis (IPT) of the Corpus Cavernosum: A Hypothesis-Generating Case Series and Review of the Literature. <i>Journal of Sexual Medicine</i> , <b>2015</b> , 12, 2118-25	1.1	6
159	Controversies on individualized prostate cancer care: gaps in current practice. <i>Therapeutic Advances in Urology</i> , <b>2013</b> , 5, 233-44	3.2	6
158	Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. <i>Asian Journal of Andrology</i> , <b>2009</b> , 11, 131-7	2.8	6
157	The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. <i>PLoS ONE</i> , <b>2020</b> , 15, e0244663	3.7	6
156	Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes. <i>World Journal of Urology</i> , <b>2021</b> , 39, 2545-2552	4	6
155	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 296.e21-296.e29	2.8	6
154	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> ,	3.3	6
153	The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients. <i>SpringerPlus</i> , <b>2016</b> , 5, 646		6
152	Evaluation of conservative approach in the management of ureteroenteric strictures following radical cystectomy with Bricker ileal conduit: a single-center experience. <i>Scandinavian Journal of Urology</i> , <b>2016</b> , 50, 439-444	1.6	6
151	Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective, Multi-institutional, Nationwide series. <i>European Urology Oncology</i> , <b>2018</b> , 1, 338-345	6.7	6
150	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. <i>Acta Oncologica</i> , <b>2021</b> , 60, 1499-1506	3.2	6

149	Elective nodal radiotherapy in prostate cancer. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e348-e357	21.7	6
148	Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients. <i>BJU International</i> , <b>2017</b> , 120, E52-E58	5.6	5
147	Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 781	5.3	5
146	Open and robotic radical prostatectomy. <i>Asian Journal of Urology</i> , <b>2019</b> , 6, 125-128	2.7	5
145	Excision and Primary Anastomosis for Bulbar Urethral Strictures Improves Functional Outcomes and Quality of Life: A Prospective Analysis from a Single Centre. <i>BioMed Research International</i> , <b>2019</b> , 2019, 7826085	3	5
144	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 246	5.3	5
143	Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 84-90	2.2	5
142	Pseudoaneurysm associated with an arteriovesical fistula after bladder substitution surgery definitively treated with a covered stent: a report of 3 cases. <i>Vascular and Endovascular Surgery</i> , <b>2013</b> , 47, 652-5	1.4	5
141	Radical prostatectomy for PSA> or =100 ng/ml prostate cancer. <i>European Urology</i> , <b>2008</b> , 54, 957-8	10.2	5
140	Urachal carcinoma during pregnancy. <i>Urology</i> , <b>2006</b> , 67, 1290.e19-21	1.6	5
139	Een beslissingshulp voor patiënten met gelokaliseerde prostaatkanker: eerste resultaten. <i>Tijdschrift Voor Geneeskunde</i> , <b>2007</b> , 63, 15-21	1	5
138	Validation of an Improved Patient-Specific Mold Design for Registration of In-vivo MRI and Histology of the Prostate. <i>Lecture Notes in Computer Science</i> , <b>2016</b> , 36-43	0.9	5
137	Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	5
136	Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
135	Nephron Sparing for Renal Cell Carcinoma: Whenever Possible?. <i>European Urology Focus</i> , <b>2016</b> , 2, 656-659.1	5	5
134	Impact of the 2014 International Society of Urological Pathology Grading System on Concept of High-Risk Prostate Cancer: Comparison of Long-Term Oncological Outcomes in Patients Undergoing Radical Prostatectomy. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1272	5.3	5
133	Intratunical injection of autologous adipose stromal vascular fraction reduces collagen III expression in a rat model of chronic penile fibrosis. <i>International Journal of Impotence Research</i> , <b>2020</b> , 32, 281-288	2.3	5
132	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 739-762	5.5	5

131	Successful Perioperative and Surgical Treatment of a Rare Case of Extra-Gastrointestinal Stromal Tumor Arising in the Prostate Gland. <i>Case Reports in Oncology</i> , <b>2019</b> , 12, 183-191	1	4
130	An unusual perineal mass in a male cyclist. <i>International Urology and Nephrology</i> , <b>2016</b> , 48, 371-2	2.3	4
129	Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2009</b> , 12, 116-23	6.2	4
128	Prepubic urethrectomy. <i>BJU International</i> , <b>2009</b> , 103, 118-32	5.6	4
127	External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer. <i>Central European Journal of Urology</i> , <b>2020</b> , 73, 19-25	0.9	4
126	Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection. <i>Journal of Urology</i> , <b>2020</b> , 203, 713-718	2.5	4
125	Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
124	A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence. <i>BJU International</i> , <b>2021</b> , 127, 575-584	5.6	4
123	Renal Neoplasm During Pregnancy: A Single Center Experience. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e501-e507	3.3	3
122	Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial. <i>World Journal of Urology</i> , <b>2017</b> , 35, 721-728	4	3
121	EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. <i>Actas Urológicas Españolas (English Edition)</i> , <b>2011</b> , 35, 501-514	0.1	3
120	A Giant Mucinous Adenocarcinoma Arising within a Villous Adenoma of the Urachus: Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , <b>2009</b> , 2009, 818646	0.7	3
119	Surveillance as an option for the treatment of small renal masses. <i>Advances in Urology</i> , <b>2008</b> , 705958	1.6	3
118	Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial. <i>BMC Cancer</i> , <b>2020</b> , 20, 457	4.8	3
117	Estimating the incidence of oligorecurrent and potentially salvageable prostate cancer on 18F-Choline PET-CT: Screening phase of the STOMP randomized phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 153-153	2.2	3
116	Metastasectomy of oligometastatic urothelial cancer: a single-center experience. <i>Translational Andrology and Urology</i> , <b>2020</b> , 9, 1296-1305	2.3	3
115	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. <i>European Urology Oncology</i> , <b>2020</b> ,	6.7	3
114	Parameters predicting [F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. <i>EJNMMI Research</i> , <b>2021</b> , 11, 41	3.6	3

113	Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by Ga-PSMA-11 PET/CT or C-Choline PET/CT: impact of postoperative treatments. <i>World Journal of Urology</i> , <b>2021</b> , 39, 399-406	4	3
112	Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
111	Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3177-3185	4	3
110	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3337-3344	4	3
109	Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores. <i>Scientific Reports</i> , <b>2018</b> , 8, 14326	4.9	3
108	Open partial nephrectomy for complex tumours and >4 cm: Is it still the gold standard technique in the minimally invasive era?. <i>Archivos Espanoles De Urologia</i> , <b>2013</b> , 66, 129-38	0.4	3
107	Current role of surgery for high risk prostate cancer. <i>Archivos Espanoles De Urologia</i> , <b>2013</b> , 66, 259-73, 259-74	0.4	3
106	Readdressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. <i>BJU International</i> , <b>2019</b> , 124, 35-39	5.6	2
105	Does Multimedia Education with 3D Animation Impact Quality and Duration of Urologists' Interactions with their Prostate Cancer Patients?. <i>Advances in Therapy</i> , <b>2015</b> , 32, 863-73	4.1	2
104	Outcomes of Salvage Radical Prostatectomy for M0 Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies?. <i>European Urology Focus</i> , <b>2021</b> , 7, 807-811	5.1	2
103	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort. <i>BJU International</i> , <b>2020</b> , 126, 704-714	5.6	2
102	Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium. <i>Pathology and Oncology Research</i> , <b>2020</b> , 26, 2605-2612	2.6	2
101	A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
100	Prophylactic ureteral catheterization in the intraoperative diagnosis of iatrogenic ureteral injury. <i>Acta Chirurgica Belgica</i> , <b>2021</b> , 121, 261-266	0.9	2
99	Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions. <i>Drugs and Aging</i> , <b>2013</b> , 30, 877-86	4.7	2
98	18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study. <i>EJNMMI Research</i> , <b>2013</b> , 3, 59	3.6	2
97	963 DEVELOPMENT AND INTERNAL VALIDATION OF A NOMOGRAM PREDICTING BIOCHEMICAL RECURRENCE AFTER EARLY SALVAGE RADIOTHERAPY IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , <b>2013</b> , 189,	2.5	2
96	PD48-03 RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER. <i>Journal of Urology</i> , <b>2017</b> , 197,	2.5	2

95	Role of carbonic anhydrase IX (CAIX) in patients with renal cell carcinoma: can we currently assess its definitive value in prognosis, prediction to treatment response and diagnosis, and as a therapeutic approach?. <i>BJU International</i> , <b>2013</b> , 111, 1015-1017	5.6	2
94	Examining the co-occurrence of bladder and prostate cancer: a worthwhile investigation?. <i>Future Oncology</i> , <b>2007</b> , 3, 515-9	3.6	2
93	127 The development and evaluation of a decision aid in the treatment of patients with localized prostate cancer. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 78, S41	5.3	2
92	A phase II study of 99mTc-trofolostat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 94-94	2.2	2
91	Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. <i>Translational Andrology and Urology</i> , <b>2020</b> , 9, 2541-2554	2.3	2
90	A Review on the Management of Small Renal Masses: Active Surveillance Versus Surgery. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2018</b> , 18, 940-950	2.2	2
89	Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trial. <i>Future Oncology</i> , <b>2020</b> , 16, 2035-2044	3.6	2
88	Guía de la EAU para el Cáncer de Próstata. <i>Actas Urológicas Españolas</i> , <b>2009</b> , 33,	0.7	2
87	Anatomical mapping of lymph nodes in patients receiving salvage lymphadenectomy based on a positive 11C-choline positron emission tomography/computed tomography scan. <i>Central European Journal of Urology</i> , <b>2019</b> , 72, 232-239	0.9	2
86	Development and external validation of a nomogram to predict lymph node invasion after robot assisted radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 37.e11-37.e20	2.8	2
85	Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 493-499	1.6	2
84	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	2
83	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 781.e17-781.e24	2.8	2
82	Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , <b>2021</b> , 25, 7890-7900	5.6	2
81	High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> ,	6.2	2
80	Surgical management of acquired rectourethral fistula: a retrospective analysis of 52 consecutive patients. <i>Techniques in Coloproctology</i> , <b>2020</b> , 24, 927-933	2.9	2
79	Current and emerging therapies for localized high-risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 267-282	3.5	2
78	Assessment of the oncological outcomes of three different bacillus Calmette-Guérin strains in patients with high-grade T1 non-muscle-invasive bladder cancer. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2021</b> , 19, 78-85	1.7	2

77	Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257195	3.7	2
76	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , <b>2021</b> , 80, 507-515	10.2	2
75	Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 937.e1-937.e9	2.8	1
74	MP87-13 IMPACT OF PRE-TREATMENT PSA LEVEL ON CANCER CONTROL AFTER EARLY SALVAGE RADIATION THERAPY POST RADICAL PROSTATECTOMY: NEED FOR PATIENT STRATIFICATION ACCORDING TO PROSTATE CANCER FEATURES. <i>Journal of Urology</i> , <b>2015</b> , 193,	2.5	1
73	Reply to Henk G. van der Poel, Tessa Buckle and Renato Valdes Olmos' letter to the editor re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2012.06.057">http://dx.doi.org/10.1016/j.eururo.2012.06.057</a> . <i>European Urology</i> , <b>2013</b> , 63, e21-2	10.2	1
72	Management of Superficial Bladder Cancer in Elderly Patients <b>2013</b> , 231-245		1
71	772 SALVAGE LYMPH NODE DISSECTION FOR PATIENTS TREATED WITH RADICAL PROSTATECTOMY WITH BIOCHEMICAL RECURRENCE AND IMAGING-DETECTED NODAL METASTASES. <i>Journal of Urology</i> , <b>2013</b> , 189,	2.5	1
70	961 PREDICTORS OF EARLY BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND ADJUVANT RADIOTHERAPY IN MEN WITH PT3N0 PROSTATE CANCER. IMPLICATIONS FOR MULTI-MODAL THERAPIES. <i>Journal of Urology</i> , <b>2013</b> , 189,	2.5	1
69	Open Radical Prostatectomy <b>2012</b> , 93-103		1
68	291 IN HIGH-RISK PROSTATE CANCER, A PELVIC LYMPH NODE DISSECTION WITH >20 LYMPH NODES REMOVED AT RADICAL PROSTATECTOMY SIGNIFICANTLY IMPROVES OVERALL SURVIVAL. <i>Journal of Urology</i> , <b>2011</b> , 185,	2.5	1
67	660 RRP AS STAND-ALONE THERAPY FOR HIGH-RISK PROSTATE CANCER. <i>Journal of Urology</i> , <b>2011</b> , 185,	2.5	1
66	The Use of Buccal Mucosa in Bulbar Stricture Repair: Morbidity and Functional Outcome <b>2011</b> ,		1
65	Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's Letter to the Editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>Eur Urol</i> <b>2011</b> ;59:572-83. <i>European Urology</i> , <b>2011</b> , 60, e39-e41	10.2	1
64	Words of wisdom. Re: Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. <i>European Urology</i> , <b>2011</b> , 60, 1121-2	10.2	1
63	Is Radical Nephroureterectomy and Lymph Node Dissection Necessary for Upper-tract TCC?. <i>European Urology Supplements</i> , <b>2010</b> , 9, 442-445	0.9	1
62	471 THE NUMBER OF POSITIVE SECTION MARGINS IN HIGH-RISK PROSTATE CANCER IS A POWERFUL AND INDEPENDENT PREDICTOR OF CANCER-SPECIFIC AND OVERALL SURVIVAL IN HIGH-RISK LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , <b>2011</b> , 185,	2.5	1
61	Surgery alone for advanced prostate cancer?. <i>European Journal of Cancer, Supplement</i> , <b>2007</b> , 5, 157-169	1.6	1
60	Benign renal mesenchymoma in the pediatric age group: a novel pathologic and karyotype entity. <i>Urology</i> , <b>2004</b> , 63, 981-4	1.6	1

59	A phase 2 study of 99m Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to histopathology: An interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e16003-e16003	2.2	1
58	Uro-oncology in the era of social distancing: the principles of patient-centered online consultations during the COVID-19 pandemic. <i>Central European Journal of Urology</i> , <b>2020</b> , 73, 260-264	0.9	1
57	Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. <i>Advances in Therapy</i> , <b>2021</b> , 1	4.1	1
56	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. <i>Ecancermedicalscience</i> , <b>2020</b> , 14, 1036	2.7	1
55	Prognostic score predicts overall survival following complete urinary tract extirpation. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 70-79	1.6	1
54	Long-Term Outcomes in Clear-Cell Renal Cell Carcinoma Patients Treated with Complete Metastasectomy. <i>Kidney Cancer</i> , <b>2020</b> , 4, 177-183	0.6	1
53	Active Surveillance and Focal Therapy: A European Perspective <b>2013</b> , 37-52		1
52	Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study. <i>Acta Oncologica</i> , <b>2020</b> , 59, 904-910	3.2	1
51	Ga-PSMA-11 PET, F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. <i>Practical Radiation Oncology</i> , <b>2021</b> , 11, 202-211 <sup>8</sup>	2.8	1
50	Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2020.11.040">https://doi.org/10.1016/j.eururo.2020.11.040</a> : Time for a Change? Clinically Meaningful Reasons Why We Will Continue to Perform Extended Pelvic Lymph Node Dissection in Selected Patients With Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 79, 154-156	10.2	1
49	In Regard to Zelefsky et al. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 910-914		1
48	Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File System. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1402	5.3	1
47	The 2014 ISUP grade group system: the Holy Grail or yet another hype?. <i>World Journal of Urology</i> , <b>2021</b> , 39, 1315-1316	4	1
46	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , <b>2021</b> , 4, 301-304	6.7	1
45	Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy. <i>International Journal of Urology</i> , <b>2021</b> , 28, 390-395	2.3	1
44	Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages T1b: a single institution, matched analysis. <i>Central European Journal of Urology</i> , <b>2018</b> , 71, 48-57	0.9	1
43	Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma.. <i>European Urology Open Science</i> , <b>2022</b> , 40, 54-57	0.9	1
42	Safety and efficacy of embolotherapy for severe hemorrhage after partial nephrectomy. <i>Acta Radiologica</i> , <b>2020</b> , 61, 1701-1707	2	0

41	A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 261-261	2.2	0
40	Prostate-Specific Antigen Modulatory Effect of a Fermented Soy Supplement for Patients with an Elevated Risk of Prostate Cancer: a Non-Randomized, Retrospective Observational Registration. <i>Current Urology</i> , <b>2020</b> , 14, 142-149	1.7	0
39	PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment. <i>BMC Medicine</i> , <b>2020</b> , 18, 213	11.4	0
38	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. <i>European Urology Open Science</i> , <b>2020</b> , 19, 16-19	0.9	0
37	Prospective comparison of simultaneous [Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. <i>European Radiology</i> , <b>2021</b> , 1	8	0
36	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101090	2.2	0
35	Re: Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>European Urology</i> , <b>2019</b> , 76, 537-539	10.2	
34	What Determines the Difference in DNA Binding Between the Androgen and the Glucocorticoid Receptors? <b>2015</b> , 59-72		
33	Re: Axel Heidenreich, David Pfister. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. <i>Eur Urol</i> 2012;62:1201-4. <i>European Urology</i> , <b>2013</b> , 64, e62-4	10.2	
32	Reply to Kwang Hyun Kim and Koon Ho Rha's letter to the editor Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. <i>Eur Urol</i> 2013;63:450-8. <i>European Urology</i> , <b>2013</b> , 64, e57-8	10.2	
31	Two-Stage Urethroplasty with Buccal Mucosa for Penoscrotal Hypospadias Reconstruction in a Male with a 46,XX Karyotype. <i>Urology Case Reports</i> , <b>2017</b> , 14, 45-47	0.5	
30	Abiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel. <i>Clinical Investigation</i> , <b>2012</b> , 2, 995-1002		
29	Adjuvant and Salvage Radiation for Advanced Prostate Cancer: A Discussion During the ESOU 2010 Meeting. <i>European Urology Supplements</i> , <b>2010</b> , 9, 401-405	0.9	
28	Introduction. Dilemmas in the field of prostate cancer detection and treatment. <i>Acta Oncologica</i> , <b>2011</b> , 50 Suppl 1, 24	3.2	
27	Reply to Endre Zoltan Neulander and Zev Wejsman Letter to the Editor re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients. <i>Eur Urol</i> 2010;58:117. <i>European Urology</i> , <b>2010</b> , 58, e37-e38	10.2	
26	Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. <i>European Urology</i> , <b>2008</b> , 53, 362	10.2	
25	Re: Bianco FJ, Scardino PT, and Eastham JA: Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("Trifecta") ( <i>Urology</i> 66(5 suppl): 83-94, 2005). <i>Urology</i> , <b>2008</b> , 71, 361	1.6	
24	Time to change the management of upper urinary tract urothelial carcinoma. <i>Central European Journal of Urology</i> , <b>2020</b> , 73, 381-382	0.9	

- 23 Focal Salvage Therapy for Prostate Cancer Recurrence After Primary Radiotherapy **2021**, 161-180
- 22 Role of Metastasectomy in Prostate Cancer Patients Following Primary Treatment **2021**, 211-221
- 21 Re: Molecular Features of Exceptional Response to Neoadjuvant Anti-androgen Therapy in High-risk Localized Prostate Cancer.. *European Urology*, **2022**, 81, 314-314 10.2
- 20 Indications for radical prostatectomy **2007**, 23-37
- 19 Salvage reconstructive surgery in an adult patient with failed previous repair of an extrophy-epispadias complex. An operation with a functional and aesthetic purpose. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2007**, 33, 810-4 2
- 18 Re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. *Eur Urol* 2017;71:766-73. *European Urology*, **2017**, 72, 121-122 10.2
- 17 Nine-year survival after iterative metastasectomies for renal cell carcinoma. *Urology Annals*, **2019**, 11, 219-221 1
- 16 Reply by Authors. *Journal of Urology*, **2020**, 204, 302 2.5
- 15 Technical Aspects of Focal Therapy in Localized Prostate Cancer: Follow-Up After Focal Therapy **2015**, 199-208
- 14 Charlson score to predict overall survival and cancer-related death in elderly patients featuring high-risk prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, 84-84 2.2
- 13 Open Radical Prostatectomy **2017**, 171-180
- 12 Chemoprevention **2017**, 29-41
- 11 Radical Prostatectomy for Locally Advanced Prostate Cancer **2009**, 281-288
- 10 Expression of PRAME and MAGE-A3 in Asian and European patients with non-small cell lung cancer (NSCLC), bladder cancer, or hepatocellular carcinoma (HCC).. *Journal of Clinical Oncology*, **2012**, 30, e13061-e13061 2.2
- 9 Retropubic Radical Prostatectomy: The Technique **2013**, 641-654
- 8 Obesity and prostate cancer research. *Central European Journal of Urology*, **2014**, 66, 428-9 0.9
- 7 Methylation-guided stratification of patients with high-risk prostate cancer for the prediction of clinical failure.. *Journal of Clinical Oncology*, **2014**, 32, 155-155 2.2
- 6 The effect of pathologic T-stage and Gleason score on cancer-specific survival for specimen-confined high-risk prostate cancer.. *Journal of Clinical Oncology*, **2014**, 32, 114-114 2.2

- 5 The effect of pathologic T-stage and Gleason score on cancer-specific survival in patients with positive surgical margins after surgery for high-risk prostate cancer.. *Journal of Clinical Oncology*, **2014**, 32, 140-140 2.2
- 4 Male Wolffian adnexal tumor: the first report of long-term follow-up after radical surgical treatment. *Current Urology*, **2021**, 15, 126-128 1.7
- 3 Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study. *Urologic Oncology: Seminars and Original Investigations*, **2022**, 40, 7.e9-7.e17 2.8
- 2 Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. *Actas Urológicas Españolas (English Edition)*, **2021**, 45, 473-478 0.1
- 1 Contemporary Role of Open Nephron Sparing Surgery **2022**, 147-155